Barbara Parente
Porto, Portugal
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 10, 2024
Lung Cancer Screening in Portugal: A PULMONALE Pilot Project
Journal: Acta medica portuguesa
Published: September 25, 2023
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects.
Journal: Cancer treatment and research communications
Published: March 13, 2023
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal.
Journal: Current oncology (Toronto, Ont.)
Published: December 01, 2022
Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel.
Journal: Pulmonology
Published: November 08, 2021
T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study.
Journal: Pulmonology
Published: November 11, 2020
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study.
Journal: Pulmonology
Published: November 06, 2019
Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer.
Journal: Current medical research and opinion
Published: May 25, 2019
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Journal: Pulmonology
Published: February 26, 2019
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Journal: Current medical research and opinion
Published: February 10, 2018
MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut.
Journal: Revista portuguesa de pneumologia
Published: February 17, 2016
Cost and Burden of Non-Small Cell Lung Cancer's in Portugal.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Last Updated: 09/26/2026